CHEK1 and non-small cell lung carcinoma: CHK1 inhibitors have potential advantages in treating NSCLC: (1) Enhanced efficacy: CHK1 inhibitors can enhance the killing effect of gemcitabine on drug-resistant cells, providing a new strategy for treating NSCLC.